SavedAdd your journal

Journals / Klimik Dergisi / 2015 / Cilt: 28 - Sayı: 2

Cross Resistance to HCV NS3 Inhibitor Developing During Treatment With Peginterferon, Ribavirin and Telaprevir

Pegile İnterferon, Ribavirin ve Telaprevir Tedavisi Altında Gelişen

Murat SAYAN
Günay ERTEM TUNCER
Şirin HEKİMOĞLU
Necla TÜLEK
Pages
92–94
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The resistance analysis may assist the selection of antiviral drugs especially in the chronic hepatitis C patients with virologic failure.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this report, a patient with chronic hepatitis C who was null responder to peginterferon and ribavirin and also developed viral rebound in the twelfth week of combination treatment with telaprevir is presented.
📊
Key Findings & Data:NS3 resistance analysis performed at the same week has shown sensitivity to paritaprevir but resistance to telaprevir, boceprevir and simeprevir.
💡
Conclusion & Impact:The resistance analysis may assist the selection of antiviral drugs especially in the chronic hepatitis C patients with virologic failure.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In this report, a patient with chronic hepatitis C who was null responder to peginterferon and ribavirin and also developed viral rebound in the twelfth week of combination treatment with telaprevir is presented. NS3 resistance analysis performed at the same week has shown sensitivity to paritaprevir but resistance to telaprevir, boceprevir and simeprevir. The resistance analysis may assist the selection of antiviral drugs especially in the chronic hepatitis C patients with virologic failure.

Özet

Bu yazıda, pegile interferon ve ribavirin tedavisine yanıtsız olan ve telaprevirli kombinasyon tedavisinin 12. haftasında viral "rebound" gelişen bir kronik hepatit C olgusu sunulmuş- tur. O dönemde yapılan HCV NS3 direnç analizi paritaprevire duyarlı, telaprevir, boseprevir ve simeprevire dirençli olarak sonuçlandı. HCV ilaç direnci analizi, özellikle virolojik başarı- sızlık gösteren kronik hepatit C hastalarında antiviral ilaçların seçiminde yol gösterici olabilir.

🔖

Cite This Article

SAYAN, M., TUNCER, G. E., HEKİMOĞLU, Ş., TÜLEK, N. (2022). Cross Resistance to HCV NS3 Inhibitor Developing During Treatment With Peginterferon, Ribavirin and Telaprevir. Klimik Dergisi, Cilt: 28 - Sayı: 2, 92–94. https://ajindex.com/articles/573616

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Mıstık R. Hepatit C virüs enfeksiyonunun epidemiyolojisi. In: Ta- bak F, Tosun S, eds. Viral Hepatit 2013. Ankara: Viral Hepatitle Savaşım Derneği, 2013: 83-112.
  2. Dilsiz G, Yenicesu İ, Belen FB, Çelik B, Öztürk G. Trends in hepa- titis B and hepatitis C virus seropositivity among blood donors over 15 years screened in the blood bank of a university hospi- tal. Transfus Apher Sci. 2012; 47(1): 95-100. [CrossRef] Altuğlu I, Söyler İ, Özaçar T, Erensoy S. Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in Western Turkey. Int J Infect Dis. 2008; 12(3): 239-44. [CrossRef] Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepa- titis C predicted by the evolution of the viral quasispecies. Sci- ence. 2000; 288(5464): 339-44. [CrossRef] Halfon P, Sarrazin C. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important? Liver Int. 2012; 32(Suppl. 1): 79-87. [CrossRef] European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepa- tol. 2014; 60(2): 392-420. [CrossRef] Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364(25): 2405-16. [CrossRef] Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untre- ated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364(13): 1195-206. [CrossRef] Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011; 364(25): 2417-28. [CrossRef] Flamm SL, Lawitz E, Jacobson I, et al. Boceprevir with peginter- feron alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol. 2013; 11(1): 81-7. [CrossRef] Sayan M.Proteaz İnhibitörlerinde Türkiye Direnç Analizi [İn- ternet]. İstanbul: Türk Klinik Mikrobiyoloji ve İnfeksiyon Has- talıkları Derneği [erişim 20 Haziran 2015]. http://www.klimik. org.tr/calisma-gruplari/viral-hepatit-calisma-grubu/atolye- turkiye-telaprevir-deneyimi-21-eylul-2013-istanbul/program-ve- sunumlar/. Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection [İnternet]. Geneva: World Health Or- ganization [erişim 20 Haziran 2015]. http://www.who.int/hiv/pub/ hepatitis/hepatitis-c-guidelines/en/. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int. 2014; 34(Suppl. 1): 6